FDA Pushes Out Decision for Cytokinetics Heart Drug to Review Proposed Safety Plan

FDA Pushes Out Decision for Cytokinetics Heart Drug to Review Proposed Safety Plan

The FDA asked Cytokinetics for the Risk Evaluation and Mitigation Strategy after it had already accepted the application for aficamten, a potential competitor to Bristol Myers Squibbs heart drug Camzyos. Analysts say this development could signal a change in FDA thinking about risk management for the broader drug class. The post FDA Pushes Out Decision for Cytokinetics Heart Drug to Review Proposed Safety Plan appeared first on MedCity News.

Another Cytokinetics own goal leaves investors fuming

Investors are frustrated by a series of recent blunders by Cytokinetics and its management team, led by CEO Robert Blum.

Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma

The FDA pushed back its decision date on Cytokinetics’ heart drug, while AstraZeneca got Phase 3 results that could help it expand use of a top drug.

Missing REMS delays Cytokinetics' heart drug PDUFA, stock drops

Cytokinetics said late Thursday that the PDUFA date for its heart disease therapy aficamten would be delayed by three months to Dec. 26. The lag would allow the FDA to review ...